Targeted Oncology· @TargetedOnc · X·· 22 hours agoScore70
Body
KEYNOTE-B49 raises a familiar oncology dilemma:
Treatment-related AE discontinuations: 11.2% vs 5.4%.
With no demonstrated OS benefit and a modest median PFS difference overall, how much additional toxicity is acceptable?
Would PD-L1 enrichment change that equation? #ESMO26
50 views · 0 likes · 0 reposts · 0 replies
Conference abstracts
LBA51matched by Proffered paper 2: Breast cancer, early and advanced stage
Results from KEYNOTE-B49: A phase 3, randomized, double-blind study of pembrolizumab (pembro) vs placebo (pbo) plus chemotherapy (CT) in participants (pts) with HR+/HER2− advanced breast cancer (ABC)
https://esmocongress.esmo.orgSource: Targeted Oncology · x.com